Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Product Launch

18 Nov 2005 07:00

Original Investments PLC18 November 2005 Original Investments PLC ("Original Investments" or "the Company") Commercial product launch from Acrobot Visualisation software, enabling orthopaedic surgeons to producethree-dimensional bone surface models from Computed Tomography (CT) scans forpre-operative surgical planning, is launched today by The Acrobot Company("Acrobot"). Acrobot is a spin-out company from Imperial Innovations, the technologycommercialization company of Imperial College, London, and develops surgicalsystems for minimally-invasive, bone-conserving orthopaedic surgery. TheAIM-quoted company Original Investments (formerly BioProjects International)owns 25% of Acrobot's equity. The new software, called the Acrobot(R) Planner, is Acrobot's first commercialproduct and is being provided free of charge to surgeons who register to use it.Acrobot will receive fees for data preparation and bone modeling. The Acrobot(R) Planner gives the user the ability to visualise a patient's threedimensional bone surface models built from CT scans. The visualisation isinteractive and the user can select and position implant models onto the bones,evaluate the resulting range of motion, and produce reports. "The software will enable surgeons to assess accurately the exact requirementfor each operation and precisely plan the procedure beforehand," says Dr. PaulaGomes, Acrobot's Director of Operations. "It will help to reduce surgicalerrors, surgeon's stress, and overall procedure costs and times. Radiologistswill also use the software to produce enhanced reports." Further uses for the software will be as a powerful tool for teaching and alsogenerating visual material for presentations. Acrobot provides a commercial service for Acrobot(R) Planner users by taking theraw CT DICOM data, segmenting them and building bone surface models from theinformation. The user can import these patient-specific models into thesoftware, and perform hip resurfacing pre-operative surgical planning and/ orimpingement analysis. The data processing service removes the need for the userto be involved in time-consuming routine data preparation tasks. The Acrobot(R) Planner has been developed by the Acrobot team at the company'slaboratories in London's Leathermarket. It is the first of a number of relatedproducts to be produced by Acrobot, which was founded six years ago by ImperialInnovations as a collaboration to combine the skills of clinicians andacademics. Acrobot is initially focusing on developing precision surgical systems forminimally-invasive techniques in knee and hip replacement. With each product theoverall aims are to reduce error, increase accuracy and enable more difficultsculpted surfaces to be achieved for the new generation of 'resurfacing' orpartial joint implants. Products planned for launch in 2006 include the Acrobot(R) Navigation System,which provides visual guidance for the surgeon and is now undergoing regulatoryapproval, and the Acrobot Hands-On Robotic System, which has already beensuccessfully proven in clinic for unicompartmental knee arthroplasty. "We are delighted that our faith in Acrobot is beginning to bear commercialfruit," said Terry Bond, managing director of Original Investments. "Four yearsago we were the first investors outside Imperial College to provide seed-cornfunding for the company and we have continued to support it through the variousstages of its development." Further information on Original Investments PLC from Terry Bond, ManagingDirector, 01235 834734. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
15th May 20187:00 amRNSYear-end Trading Update and £2.5m Fundraising
30th Apr 20184:00 pmRNSNotice of Trading Update
29th Mar 20187:00 amRNSPremaitha to attend industry conferences in APAC
26th Mar 20187:00 amRNSUpdate on UK patent infringement claim
16th Feb 20187:00 amRNSPremaitha secures market entry into Egypt
14th Feb 201810:25 amRNSHolding(s) in Company
12th Feb 20187:00 amRNSThermo Fisher - issue of warrants
6th Feb 20187:00 amRNSPremaitha to attend key conferences in Middle East
5th Feb 20187:00 amRNSPremaitha's IONA test approved for sale in Brazil
24th Jan 20187:00 amRNSUK High Court grants right to appeal
22nd Jan 20187:00 amRNSSecured loan facility agreement with Thermo Fisher
29th Dec 20177:00 amRNSHalf Year Results
11th Dec 20177:00 amRNSPremaitha secures four further laboratories in EU
1st Dec 20179:40 amRNSPremaitha CEO Wins Outstanding Contribution Award
27th Nov 20177:00 amRNSMiddle East laboratory network expansion
23rd Nov 20177:00 amRNSPremaitha signs new partner in East Asia
21st Nov 201710:47 amRNSLitigation First Instance Judgment
30th Oct 201710:08 amRNSGrant of Share Options
24th Oct 20173:45 pmRNSResult of AGM
24th Oct 20177:00 amRNSAGM Statement
13th Oct 20177:00 amRNSMiddle East Update
29th Sep 20177:04 amRNSFinal Results
29th Sep 20177:01 amRNSNotice of AGM
21st Sep 20174:05 pmRNSHolding(s) in Company
19th Sep 20177:00 amRNSPremaitha to offer NIPT in South Africa
7th Sep 20173:10 pmRNSFurther Patent Infringement Claims
29th Aug 20177:00 amRNSApproved for Good Manufacturing Process in Brazil
18th Jul 20172:02 pmRNSHolding(s) in Company
12th Jul 20177:00 amRNSInvestment Agreement Extension with Thermo Fisher
10th Jul 20177:00 amRNSPremaitha announces two laboratory hub contracts
3rd Jul 20177:00 amRNSLitigation Update
27th Jun 20177:00 amRNSHolding(s) in Company
16th Jun 20177:00 amRNSPremaitha launches Sage NIPT solution
5th Jun 20177:00 amRNSIndia Business Update
26th May 20177:00 amRNSIONA test validation on Thermo Fisher's Ion S5
19th May 20172:30 pmRNSPremaitha welcomes NIPT recommendation in France
16th May 20177:00 amRNSYear End Trading Update
12th May 20172:15 pmRNSUpdate Re. Swiss Customer
3rd Apr 20174:48 pmRNSHolding(s) in Company
31st Mar 20174:00 pmRNSSecond tranche of warrants issued to Thermo Fisher
17th Mar 20177:15 amRNSHardman Research: Expanding global distribution
13th Mar 20177:00 amRNSPremaitha to Attend International Medical Events
2nd Mar 201711:03 amRNSCompletion of Yourgene Acquisition
27th Feb 20177:00 amRNSCompletion of Acquisition
22nd Feb 20179:37 amRNSHolding(s) in Company
20th Feb 20177:00 amRNSMiddle East Business Update
16th Feb 20175:34 pmRNSHolding(s) in Company
15th Feb 20177:00 amRNSIssue of Equity
14th Feb 20179:32 amRNSHolding(s) in Company
13th Feb 20177:00 amRNSNew partnership with European diagnostics group

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.